Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imlygic

- PMLiVE

Amgen’s Lumakras shows promising results for patients with non-small cell lung cancer

Results from the phase 3 trial demonstrated superiority over standard of care Docetaxel chemotherapy in KRAS G12C-mutated non-small cell lung cancer

- PMLiVE

Amgen announces positive results for Solaris biosimilar for paroxysmal nocturnal haemoglobinuria

ABP 959 demonstrated no ‘clinically meaningful’ difference to the reference product in the phase 3 study

- PMLiVE

Amgen to acquire ChemoCentryx in $3.7bn cash deal

The agreement includes the acquisition of ChemoCentryx’s autoimmune disease treatment Tavneos

- PMLiVE

Boehringer Ingelheim and QUANTRO Therapeutics partner to develop drug candidates

The collaboration aims to offer a long-term strategy to provide breakthrough cancer treatments

- PMLiVE

AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab

The INTERLINK-1 study assessed the combination drug candidate to treat patients with head and neck cancer

- PMLiVE

Boehringer Ingelheim and VisionHealth collaborate on distribution of digital Kata platform

The app provides therapy support to those with with asthma and chronic obstructive pulmonary disease

- PMLiVE

Evotech, Boehringer Ingelheim and bioMérieux launch joint venture to combat antimicrobial resistance

The joint company, Aurobac Therapeutics SAS, will create the next generation of antimicrobials along with actionable diagnostics to combat antimicrobial resistance

- PMLiVE

First evidence-based guide launched to put patients at heart of digital innovations

Produced by the University of Plymouth, the Academic Health Science Network and Boehringer Ingelheim, the guide follows the UK government’s plan to revolutionise digital health and social care

- PMLiVE

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

Rheumatoid arthritis is a long-term condition that causes painful swelling and stiffness in the joints

- PMLiVE

Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data

The potential new oral treatment showed a reduction in lung function decline

regeneron headquarters

Regeneron set to acquire Checkmate for approximately $250m

The deal is expected to be finalised in mid-2022

- PMLiVE

Amgen’s biosimilar delivers impressive phase 3 results for psoriasis compared to Janssen’s Stelara

The biosimilar was seen to have no clinically meaningful differences to Stelara

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links